Cargando…

Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data

INTRODUCTION: Concizumab enhances thrombin generation (TG) potential in haemophilia patients by inhibiting tissue factor pathway inhibitor (TFPI). In EXPLORER3 (phase 1b), a dose‐dependent pharmacokinetic/pharmacodynamic (PK/PD) relationship was confirmed between concizumab dose, free TFPI and TG po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichler, Hermann, Angchaisuksiri, Pantep, Kavakli, Kaan, Knoebl, Paul, Windyga, Jerzy, Jiménez‐Yuste, Victor, Harder Delff, Philip, Chowdary, Pratima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379180/ https://www.ncbi.nlm.nih.gov/pubmed/30408848 http://dx.doi.org/10.1111/hae.13627

Ejemplares similares

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab
por: Chowdary, Pratima
Publicado: (2018)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives
por: Pasca, Samantha
Publicado: (2022)

Management of haemophilia A with inhibitors: A regional cross‐talk
por: Peyvandi, Flora, et al.
Publicado: (2022)

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia
por: Boonyawat, Kochawan, et al.
Publicado: (2022)

Cancer-associated thrombosis in Asia
por: Angchaisuksiri, Pantep
Publicado: (2016)

Gene therapy in haemophilia: literature review and regional perspectives for Turkey
por: Kavaklı, Kaan, et al.
Publicado: (2022)

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
por: Yaish, Hassan, et al.
Publicado: (2019)

Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study
por: Khair, Kate, et al.
Publicado: (2021)

Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation
por: de Laat-Kremers, Romy M. W., et al.
Publicado: (2021)

Using theory of change to co-create a programme theory for a telerehabilitation intervention for pain management in people with haemophilia
por: McLaughlin, Paul, et al.
Publicado: (2023)

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
por: Chuansumrit, Ampaiwan, et al.
Publicado: (2010)

Examining patient and professional perspectives in the UK for gene therapy in haemophilia
por: Woollacott, Ione, et al.
Publicado: (2022)

Pain and pain management in haemophilia
por: Auerswald, Günter, et al.
Publicado: (2016)

A quality‐of‐life questionnaire for heavy menstrual bleeding in Thai women receiving oral antithrombotics: Assessment of the translated Menstrual Bleeding Questionnaire
por: Rodpetch, Tinaram, et al.
Publicado: (2021)

The Evaluation of Pharmacodynamics and Pharmacokinetics of Anti-thrombin DNA Aptamer RA-36
por: Zavyalova, Elena, et al.
Publicado: (2017)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: post hoc subanalysis of the randomized, phase 3 PROPEL study
por: Escuriola-Ettingshausen, Carmen, et al.
Publicado: (2023)

S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
por: Kenet, Gili, et al.
Publicado: (2023)

Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery
por: Pabinger, Ingrid, et al.
Publicado: (2021)

Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports
por: Wang, Michael, et al.
Publicado: (2016)

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Impaired platelet‐dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro
por: Chowdary, Pratima, et al.
Publicado: (2020)

Switching treatments in haemophilia: is there a risk of inhibitor development?
por: Santagostino, Elena, et al.
Publicado: (2015)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

Left ventricular thrombus and pulmonary embolism: A case series of thrombosis in COVID‐19 in Thai patients
por: Nanthatanti, Nithita, et al.
Publicado: (2020)

Legg on Hæmophilia
Publicado: (1873)

Malarious Hæmophilia
Publicado: (1890)

The Treatment of Haemophilia
por: Biggs, Rosemary
Publicado: (1969)

Living with Haemophilia
por: Laffan, Mike
Publicado: (1995)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Comparison of joint status using ultrasound assessments and Haemophilia Joint Health Score 2.1 in children with haemophilia
por: Li, Yanju, et al.
Publicado: (2023)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais
por: Noikongdee, Phichchapha, et al.
Publicado: (2021)

Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais
por: Boonyawat, Kochawan, et al.
Publicado: (2023)

International consensus recommendations on the management of people with haemophilia B
por: Hart, Daniel P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rr4tgl98g5juss3jds8li8num1